The 8 most recent market catalysts affecting $PSNL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M
Personalis, Inc. announced a new task order valued at up to $18.3 million under its existing contract with the U.S. Department of Veterans Affairs for the Million Veteran Program (…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
Personalis Q2 EPS $(0.30) Misses $(0.27) Estimate, Sales $22.357M Beat $16.783M Estimate
Personalis (PSNL) released its Q2 earnings, presenting a mixed financial picture. The company's sales of $22.357 million significantly surpassed analyst expectations and demonstrat…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 65
Lake Street Downgrades Personalis to Hold, Announces $16.25 Price Target
Lake Street analyst Thomas Flaten downgraded Personalis (PSNL) from a 'Buy' to a 'Hold' rating and established a new price target of $16.25. This downgrade indicates a less optimis…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 95
Personalis shares are trading lower after Tempus AI announced a definitive agreement to acquire Personalis in a $1.5 billion deal.
This is a major corporate catalyst directly impacting Personalis (PSNL) shareholders. The fact that PSNL shares are trading lower post-announcement suggests the $1.5 billion valuat…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Personalis, Raises Price Target to $16.25
BTIG analyst Mark Massaro has maintained a 'Buy' rating for Personalis (PSNL) and significantly raised the price target from $11 to $16.25. This action signals increased confidence…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Personalis, Raises Price Target to $17
Needham analyst Mike Matson maintained a 'Buy' rating on Personalis and raised the price target from $12 to $17. This indicates a strengthened conviction in the company's prospects…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test
Personalis has achieved UKCA designation for its NeXT Personal Dx test, a critical regulatory milestone that permits its clinical use across Great Britain. This is significant beca…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.